CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women Readmission and Mortality After Hospitalization for Myocardial Infarction and Heart Failure Myeloid-Derived Growth Factor Protects Against Pressure Overload–Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca2+-ATPase Expression in Cardiomyocytes Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure

Original Research2019 May;21(5):665-675.

JOURNAL:Eur J Heart Fail. Article Link

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF